About Dimethyl Fumarate API
Therapeutic CategoryCentral Nervous System (CNS)
CAS Number
624-49-7
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, EUDMF, Brazil DMF, China DMF
Mechanism of Action
The mechanism by which dimethyl fumarate (DMF) exerts its therapeutic effect in multiple sclerosis is unknown. DMF and the metabolite, monomethyl fumarate (MMF), have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
Indication
TECFIDERA is indicated for the treatment of patients with relapsing forms of multiple sclerosis
Related APIs
Eslicarbazepine Acetate
Central Nervous System (CNS)
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!